Here is the transcript of the exclusive interview on CNBC-TV18. Also watch the accompanying video.
Q: What exactly does one mean when one talks about instruments of fund raising?
Nayar: I think as a company looks at its growth plans and capital expenditure requirements, they obviously take care of it through internal resources first. Over and above that they have options of raising either debt or equity. Within equity also there can be pure equity or convertibles, which are equity like instruments which get converted to equity or can stay as debt.
Q: Is this always done in order to do capital raising or sometimes it is also done in order to get in a strategic investor etc. In that, are there different layers to why a company chooses to do fund raising or is it just as simple as the capex issue?
Hot Rising Stocks To Buy Right Now: Accuride Corporation New (ACW)
Accuride Corporation, together with its subsidiaries, engages in designing, manufacturing, marketing, and supplying commercial vehicle components in North America. The company offers heavy- and medium-duty steel and aluminum wheels, light truck steel wheels, and military wheels; and wheel-end components and assemblies, such as brake drums, disc wheel hubs, spoke wheels, disc brake rotors, and automatic slack adjusters. It also provides truck body and chassis parts comprising bumpers, fuel tanks, battery boxes and toolboxes, front-end cross members, muffler assemblies, and crown assemblies and components, as well as fenders, exhaust components, sun visors, windshield masks, step assemblies, brackets, fuel tank supports, inner-hood panels, door assemblies, dash panel assemblies, and various other components. In addition, the company offers ductile and gray iron casting of transmission and engine-related components, which comprise flywheels, and transmission and engine-relate d housings and brackets; and ductile and gray iron casting of industrial components, such as flywheels, pump housings, small engine components, and other industrial components. Accuride Corporation markets its products under Accuride, Gunite, Imperial, and Brillion brand names. It serves heavy- and medium-duty truck, and commercial trailer original equipment manufacturers (OEM); and aftermarket suppliers, including OEM dealer networks, wholesale distributors, and aftermarket buying groups. The company was founded in 1986 and is headquartered in Evansville, Indiana.
Advisors' Opinion:- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Accuride (NYSE: ACW ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Accuride doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue decreased 14.3%, and inventory decreased 30.5%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue dropped 28.6%, and inventory dropped 30.5%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 9.2%, and inventory dropped 6.1%.
Top Gas Utility Stocks To Own For 2014: Credit Acceptance Corporation(CACC)
Credit Acceptance Corporation, together with its subsidiaries, provides auto loans, and related products and services to consumers in the United States. Its loan programs include portfolio program, which advances money to dealer-partners in exchange for the right to service the underlying consumer loans; and purchase program that buys the consumer loans from the dealer-partners and keeps amounts collected from the consumers. The company markets its products through a network of approximately 55,000 independent and franchised automobile dealers. Credit Acceptance Corporation was founded in 1972 and is headquartered in Southfield, Michigan.
Advisors' Opinion:- [By Richard Moroney]
Credit Acceptance (CACC) provides financing for auto purchases through a national network of nearly 4,500 car dealers. Its programs help dealers sell cars by attracting credit-challenged consumers unable to get conventional loans.
- [By Eric Volkman]
Credit Acceptance (NASDAQ: CACC ) will see big blocks of its shares change hands over the next few days. The company has specified the pricing of a previously announced underwritten public secondary stock common offering of $105.00 per share. Trusts associated with the firm's founder Donald Foss, in combination with Karol Foss and people and entities connected with Prescott General Partners, aim to sell a combined 1.5 million of their shares. Additionally, the underwriters will have a 30-day option to buy up to an extra 225,000 shares.
Top Gas Utility Stocks To Own For 2014: Lithia Motors Inc. (LAD)
Lithia Motors, Inc. operates as an automotive franchisee and retailer of new and used vehicles in the United States. The company sells new and used cars, and trucks; offers replacement parts; provides vehicle maintenance, warranty, paint, and repair services; and arranges related financing, service contracts, protection products, and credit insurance. As of February 22, 2013, the company offered 27 brands of new vehicles and various brands of used vehicles in 87 stores, as well as online at Lithia.com. Lithia Motors, Inc. was founded in 1946 and is based in Medford, Oregon.
Advisors' Opinion:- [By Inyoung Hwang]
Ladbrokes (LAD) rallied 2.9 percent to 185 pence, posting the biggest two-day gain since April 2009. A mystery buyer, thought to be Sagi, bought a stake in the U.K. bookmaker, the Telegraph reported. The deal, through Shore Capital, was just below the 3 percent disclosure limit, according to the Telegraph. The purchase fueled speculation about a possible bid, the newspaper said.
Top Gas Utility Stocks To Own For 2014: NewLink Genetics Corp (NLNK)
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.
The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.
HyperAcute Cancer Immunotherapy Product Candidates
In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.
HyperAcute Cancer Immunotherapy Technology
The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.
IDO Pathway Inhibitor Product Candidate
The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.
Advisors' Opinion:- [By Ben Levisohn]
Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [the Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira�(TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and likely to attract additional funding.”
- [By Matt Egan]
Another big winner on Wednesday is NewLink Genetics (NLNK), which has the exclusive license to an experimental Ebola vaccine developed by the Public Health Agency of Canada. The FDA recently gave approval for Phase 1 clinical trials on the drug. Shares of NewLink are up 8%.
- [By Ben Rooney]
NewLink Genetics (NLNK) is working with the World Health Organization and other agencies on an Ebola vaccine. Its shares have surged 57% in the past month.
Top Gas Utility Stocks To Own For 2014: Wyndham Worldwide Corp(WYN)
Wyndham Worldwide Corporation, together with its subsidiaries, provides various hospitality products and services to individual consumers and business customers in the United States and internationally. It offers its products and services under the Wyndham Hotels and Resorts, Ramada, Days Inn, Super 8, Howard Johnson, Wyndham Rewards, Wingate by Wyndham, Microtel, RCI, The Registry Collection, ResortQuest, Landal GreenParks, Novasol, Hoseasons, cottages4you, James Villa Holidays, Wyndham Vacation Resorts, and WorldMark by Wyndham brand names. The company?s Lodging segment franchises hotels in the upscale, midscale, economy, and extended stay markets of the lodging industry, as well as provides hotel management services for full-service hotels. Its Vacation Exchange and Rentals segment provides vacation exchange products and services, as well as access to distribution systems and networks to resort developers and owners of intervals of vacation ownership interests (VOIs); a nd markets vacation rental properties primarily on behalf of independent owners, vacation ownership developers, and other hospitality providers. Wyndham Worldwide Corporation?s Vacation Ownership segment develops and markets VOIs to individual consumers; and provides consumer financing in connection with the sale of VOIs, as well as offers property management services at resorts. The company is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By John Udovich]
Small cap hotel stock La Quinta Holdings Inc (NYSE: LQ) just had its IPO to raise a lower than expected $650 million after being priced below its expected range, meaning its worth taking a closer look at the stock which�is focused on the�mid-priced hotel market along with the performance of potential benchmarks like hotel stocks Marriott International Inc (NASDAQ: MAR), Choice Hotels International Inc (NYSE: CHH) and Wyndham Worldwide Corporation (NYSE: WYN).
- [By Monica Gerson]
Wyndham Worldwide (NYSE: WYN) is estimated to report its Q3 earnings at $1.36 per share on revenue of $1.41 billion.
Northrop Grumman (NYSE: NOC) is expected to report its Q3 earnings at $1.82 per share on revenue of $5.96 billion.
- [By Dimitra DeFotis]
Apartment Invest & Management (AIV)
Ameriprise (AMP)
Edison International (EIX)
Host Hotels & Resorts (HST)
Kimco Realty (KIM)
Kroger (KR)
Lincoln National (LNC)
Newfield Exploration (NFX)
Republic Services (RSG)
UnitedHealth (UNH)
Verizon (VZ)
Wells Fargo (WFC)
WellPoint (WLP)
Wyndham Worldwide (WYN)
Xcel Energy Utilities (XEL)
Top Gas Utility Stocks To Own For 2014: Hutchinson Technology Inc (HTCH)
Hutchinson Technology Incorporated (HTI), incorporated on October 29, 1965, is a global technology manufacturer. The Company is a supplier of suspension assemblies for hard disk drives. The Company operates in two segments: the Disk Drive Components Division and the BioMeasurement Division. The Company manufactures suspension assemblies for all sizes and types of hard disk drives. Suspension assemblies are components of disk drives that hold the read/write heads in position above the spinning magnetic disks.
The Company categorize its products as either suspension assemblies or other revenue, which consists primarily of revenue outside of the disk drive industry for precision component manufacturing, tool design, tool build and metrology, suspension assembly components, reimbursement for disk drive industry-related engineering services and specific disk drive program capacity and biomeasurement products. During the year ended September 29, 2013, the Company shipped 404 million suspension assemblies of all types, supplying all manufacturers of disk drives and head-gimbal assemblers.
The Company competes with Nihon Hatsujo Kabusikigaisha, Magnecomp Precision Technology Public Company Limited, NAT Peripheral (H.K.) Co., Ltd., Nitto Denko Corporation and Dai Nippon Corporation.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 electronic component player that's starting to move within range of triggering a big breakout trade is Hutchinson Technology (HTCH), which is a technology manufacturer that creates value by developing solutions to critical customer problems. This stock has been on fire during 2013, with shares up a whopping 75%.
If you take a look at the chart for Hutchinson Technology, you'll notice that this stock has been finding significant buying interest over the last two months, whenever it has pulled back to around $3.30 to $3.20 a share. This pattern could be signaling that shares of HTCH are forming a major bottoming chart pattern if those levels can hold as support. Shares of HTCH are now starting to flirt with its 50-day moving average at $3.56 a share. That move is starting to push the stock within range of triggering a big breakout trade above a key downtrend line.
Market players should now look for long-biased trades in HTCH if it manages to break out above its 200-day moving average of $3.65 a share and then once it clears more overhead resistance levels at $3.89 to $4.13 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 392,134 shares. If that breakout triggers soon, then HTCH will set up to re-test or possibly take out its next major overhead resistance levels at $4.75 to $5.50 a share, or even $6 a share.
Traders can look to buy HTCH off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.37 or at $3.17 a share. One can also buy HTCH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment